Among the highlights of UK Chancellor John Healey's first Budget was more than £1 billion in investment by Convatec, Vertex ...

While Lilly's injectable incretin products are romping away, the performance of its oral GLP-1 agonist Foundayo (orforglipron) – currently competing head-to-head with Novo's first-to-market Wegovy ...

Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively ...

While Anthropic has not disclosed the number of shares to be released, their price range, or a date for the listing, ...

Switzerland's Ferring Pharma has reached an agreement to buy US women's health startup Gameto for up to $1.38 billion, ...

AbbVie has filed for FDA approval of its T-cell engager (TCE) etentamig in relapsed or refractory multiple myeloma, a key ...

The Novartis Pavillon in Park South of the Novartis Campus in Basel, Switzerland. Novartis's third-quarter results included a ...

Shares in GSK fell today on a 2% decline in vaccine sales in the third quarter, although demand for other medicines was strong and there are signs that the revamp of the business under new management ...

Moderna and MSD have shared keenly anticipated results for their melanoma cancer vaccine, ahead of a presentation at ESMO ...

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met the company's high expectations, with a head-to-head win ...

There is a moment, somewhere in a pharma content workflow, when a draft stops being a draft and becomes an action – sent, routed, acted on. Agentic AI is pulling that moment earlier and earlier, ...

UK biotech sector has shrugged off a difficult economic environment with a 44% increase in venture capital investment in the ...